AR063721A1 - Derivados de anilinopiperazina y composicion farmaceutica - Google Patents

Derivados de anilinopiperazina y composicion farmaceutica

Info

Publication number
AR063721A1
AR063721A1 ARP070104809A ARP070104809A AR063721A1 AR 063721 A1 AR063721 A1 AR 063721A1 AR P070104809 A ARP070104809 A AR P070104809A AR P070104809 A ARP070104809 A AR P070104809A AR 063721 A1 AR063721 A1 AR 063721A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
aryl
haloalkyl
heterocyclyl
Prior art date
Application number
ARP070104809A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR063721A1 publication Critical patent/AR063721A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La presente invención se refiere a derivados de anilinopiperazina, y a composiciones que comprenden los derivados de anilinopiperazina. Estos compuestos son útiles para prevenir un trastorno proliferativo, un trastorno antiproliferativo, inflamación, artritis, un trastorno del sistema nervioso central, una enfermedad cardiovascular, alopecia, una enfermedad neuronal, una lesión isquémica, una enfermedad viral, una infección fúngica o un trastorno relacionado con la actividad de una proteína quinasa. Reivindicación 1: Un compuesto que tiene la fórmula (1) o una de sus sales, solvatos, ésteres, profármacos o estereoisómeros farmacéuticamente aceptables, en donde la línea de puntos indica un enlace opcional y adicional y en donde: R1 es H, alquilo, alquenilo, alquinilo, halo, -(alquilen)m-arilo, -alquenilenarilo, -alquinilen-arilo, -(alquilen)mcicloalquilo, -(alquilen)m-heteroarilo, -(alquilen)m-heterociclilo, -(alquilen)m-heterociclenilo, en donde cualquier arilo, cicloalquilo, heteroarilo, heterociclilo o heterociclenilo puede estar opcionalmente sustituido con hasta 5 sustituyentes, que pueden ser iguales o diferentes, y están seleccionados, de modo independiente, de halo, alquilo, cicloalquilo, - (alquilen),N(R9)2, -(alquilen)m-O-alquilo, -O-arilo, -C(O)R8, -S-alquilo, -O-arilo, -(alquilen)m-CN, alquinilo, alquenilo, hidroxialquIlo, haloalquilo, -O-haloalquiLo, -C(O)OR7, -NHC(O)R7, -C(O)N(R7)2, -S(O)2N(R8)2, -NHS(O)2R8, -(alquilen)m- heteroarilo, - (alquilen)m-heterociclilo y -(alquilen)m-arilo; en donde un grupo alquilo, alquenilo o alquinilo puede estar sustituido con uno o varios sustituyentes, que pueden ser iguales o diferentes, y están seleccionados, de modo independiente, de halo, alquilo, -N(R7)2, -C(O)OH, arilo, y -O-alquilo; en donde cualquier grupo cíclico R1 puede estar opcionalmente fusionado a un grupo cicloalquilo, arilo, heteroarilo o heterociclilo; de modo que, cuando R1 es heteroarilo, heterociclilo o heterociclenilo, estos grupos están unidos al resto del compuesto de la fórmula (1) por medio de un átomo de carbono del anillo; R2 es H, alquilo, haloalquilo, hidroxialquilo, -(alquilen)m-C(O)N(R8)2, -(alquilen)-NHC(O)-R9 o -(alquilen)m-N(R9)2, o R2 y el átomo de carbono del anillo al que está unido forma un grupo carbonilo; R3 es H, -alquilo, haloalquilo, hidroxialquilo, -(alquilen),-C(O)N(R8)2, -(alquilen)m-NHC(O)-R9 o -(alquilen)m-N(R9)2, o R3 y R3a, junto con el átomo de carbono común al que están unidos, se juntan para formar un grupo carbonilo, cicloalquilo o heterociclilo; R3a es H, -alquilo, haloalquilo, hidroxialquilo, -(alquilen)m-C(O)N(R8)2, - (alquilen)m-NHC(O)-R9 o -(alquilen)m-N(R9)2; cada aparición de R4 es, de modo independiente, H, -alquilo, -(alquilen)m-arilo, -(alquilen)m-heteroarilo, -(alquilen)m-heterociclilo, -(alquilen)m-N(R8)2, -(alquilen)m-OH, -(alquilen)m-NHC(O)R8, hidroxialquilo, haloalquilo, -CH2NH2, -C(O)R5, -C(O)OR8, -C(O)-(alquilen)m-N(R8)2, - C(O)NH-alquilo, -C(O)N(alquil)2, -(alquilen)-NHC(O)R6, -NHC(O)OR8, -CR2C(O)NH2, -CR2C(O)NH(alquilo), -CR2C(O)NH(alquilo)2 o -NHS(O)2R6; R5 es H, alquilo, arilo, -heteroarilo o -NHOH; cada aparición de R6 es, de modo independiente, H, alquilo, arilo o haloalquilo; cada aparición de R7 es H, -OH, alquilo, -O-alquilo, cicloalquilo o haloalquilo; cada aparición de R8 es, de modo independiente, H, alquilo, -(alquilen)m-arilo, -(alquilen)m-heterociclilo, -(alquilen)m-heteroarilo o -(alquilen)m- cicloalquilo; cada aparición de R9 es H, aquilo, haloalquilo, hidroxialquilo, -(alquilen)m-arilo, -(alquilen)m-heterociclo, -(alquilen)m-heteroarilo o -(alquilen)m-cicloalquilo; R10 es H, -alquilo, haloalquilo, hidroxialquilo, -(alquilen)m- C(O)N(R8)2, -(alquilen)m-NHC(O)-R9 o -(alquilen)m-N(R9)2, o R10 y R10a, junto con el átomo de carbono común al que están unidos, se juntan para formar un grupo carbonilo, cicloalquilo o heterociclilo; R10a es H, -alquilo, haloalquilo, hidroxialquilo, -(alquilen)m-C(O)N(R8)2, -(alquilen)m-NHC(O)-R9 o -(alquilen)m-N(R9)2; cada aparición de R11 es, de modo independiente, H, alquilo, haloalquilo, hidroxialquilo, -(alquilen)m-C(O)N(R8)2, -(alquilen)m-NHC(O)-R9 o -(alquilen)m-N(R9)2, o cualquier R11 y el átomo de carbono del anillo al que está unido forma un grupo carbonilo; cada aparición de R12 es, de modo independiente, H, alquilo, -(alquilen)m-arilo, -(alquilen)m-heteroarilo, -(alquilen)m-heterociclilo, -S(O)2-alquilo, -S(O)2- arilo, -S(O)2-heteroarilo, hidroxialquilo, -C(O)R8, o -C(O)OR8; Ar es arileno o heteroarileno, en donde el arileno o heteroarileno se juntan a través de 2 de sus átomos de carbono del anillo adyacentes, y en donde el grupo arileno o heteroarileno puede estar opcionalmente sustituido con hasta 4 sustituyentes, que pueden ser iguales o diferentes, y están seleccionados, de modo independiente, de halo, alquilo, -OH, -OR9, -(alquilen)m-N(R6)2 -N(alquilo)2, -SR9, -S(O)R8, -S(O)2R8, -S(O)2NHR9, - C(O)R8, -C(O)OR9, -(alquilen)m-C(O)N(R8)2, -NHC(O)R9, haloalquilo, hidroxialquilo, -CN y NO2, de modo que, cuando Ar es tetrahidronaftileno, R2 y son cada uno distintos de hidrógeno; W es -N(R12)-, -S-, -O- o -C(R4)2-, en donde ambos grupos R4 y el átomo de carbono común al que están unidos se pueden combinar para formar un grupo cicloalquilo o heterociclilo, cada uno de los cuales también pueden estar sustituidos; Y es H, halo, alquilo o -CN; Z es -C(R7)- o -N-, de modo que, cuando el enlace adicional opcional está presente, Z es -C(R7)-; cada aparición de m es, de modo independiente, 0 ó 1; n es un número entero de 0 a 2; y p es 0 ó 1.
ARP070104809A 2006-10-31 2007-10-30 Derivados de anilinopiperazina y composicion farmaceutica AR063721A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85565406P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
AR063721A1 true AR063721A1 (es) 2009-02-11

Family

ID=39238269

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104809A AR063721A1 (es) 2006-10-31 2007-10-30 Derivados de anilinopiperazina y composicion farmaceutica

Country Status (12)

Country Link
US (1) US9206142B2 (es)
EP (1) EP2078003B1 (es)
JP (1) JP5063700B2 (es)
KR (1) KR20090075873A (es)
CN (1) CN101578275A (es)
AR (1) AR063721A1 (es)
AU (1) AU2007314342B2 (es)
CA (1) CA2668210C (es)
IL (1) IL198397A0 (es)
MX (1) MX2009004786A (es)
TW (1) TW200829583A (es)
WO (1) WO2008054702A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090004976A (ko) * 2006-04-19 2009-01-12 아스테라스 세이야쿠 가부시키가이샤 아졸카르복사미드 유도체
WO2009054468A1 (ja) 2007-10-24 2009-04-30 Astellas Pharma Inc. アゾールカルボキサミド化合物又はその塩
JP5224616B2 (ja) * 2007-10-29 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環式エーテルまたはチオエーテル誘導体
US8476278B2 (en) * 2007-10-29 2013-07-02 Merck Sharp & Dohme Corp. Thiazole Derivatives as protein kinase inhibitors
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
EP2070916A1 (de) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
PE20091577A1 (es) * 2008-03-03 2009-11-05 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
WO2010026124A1 (en) 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
WO2010126811A1 (en) 2009-04-27 2010-11-04 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
JP5567136B2 (ja) * 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
ES2601004T3 (es) * 2010-04-07 2017-02-13 F. Hoffmann-La Roche Ag Compuestos pirazol-4-il-heterociclil-carboxamida y métodos de uso
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
US20130165450A1 (en) * 2010-09-14 2013-06-27 Hon-Chung Tsui Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors
CN103270029B (zh) 2010-10-22 2016-01-20 拜耳知识产权有限责任公司 作为农药的杂环化合物
EP2681197A1 (en) * 2011-03-04 2014-01-08 Novartis AG Tetrasubstituted cyclohexyl compounds as kinase inhibitors
TWI570117B (zh) 2011-09-27 2017-02-11 赫孚孟拉羅股份公司 吡唑－４－基－雜環甲醯胺化合物及使用方法
CN102603667B (zh) * 2012-02-10 2014-04-30 合肥工业大学 一种n-(2-氯-6-甲基苯基)-2-(苯丙烯酰胺)噻唑-5-甲酰胺衍生物、其制备方法及其用途
SG11201406185WA (en) 2012-03-30 2014-11-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
PE20150194A1 (es) 2012-05-21 2015-02-08 Novartis Ag Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
EP2900661B1 (en) * 2012-09-28 2016-10-26 Bayer CropScience AG Quinoline isoxazolin derivatives for plant disease control
CN102993124B (zh) * 2012-11-25 2014-12-10 大理学院 取代哌嗪类化合物及其制备方法和药物用途
CN104211639A (zh) * 2013-06-05 2014-12-17 中国科学院上海药物研究所 一类炔基杂环类化合物及其应用
EP3010920A1 (en) * 2013-06-18 2016-04-27 4SC Discovery GmbH 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors
CN103342703B (zh) * 2013-07-22 2015-07-29 湖南大学 N-[4-(苯并呋喃-5-基)噻唑-2-基]酰胺及其制备方法与应用
BR112016010041B1 (pt) * 2013-11-08 2023-04-18 Takeda Pharmaceutical Company Limited Composto heterocíclico com uma ação inibitória de irak-4, composição farmacêutica, e, uso do composto
UA120754C2 (uk) * 2013-12-20 2020-02-10 Естеве Фармасьютікалс, С.А. Похідні піперазину, які характеризуються мультимодальною активністю відносно болю
WO2015090224A1 (zh) 2013-12-20 2015-06-25 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途
GB201406956D0 (en) * 2014-04-17 2014-06-04 Univ Nottingham Compounds
WO2017013210A1 (en) * 2015-07-21 2017-01-26 4Sc Ag Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds
EP3736272A1 (en) * 2015-09-14 2020-11-11 The National Institute for Biotechnology in the Negev Ltd. Novel piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting vdac oligomerization, apoptosis and mitochondria dysfunction
GB201518365D0 (en) 2015-10-16 2015-12-02 Exonate Ltd Compounds
US10125123B2 (en) * 2016-03-03 2018-11-13 Cornell University Small molecule IRE1-α inhibitors
RU2731095C2 (ru) 2016-03-17 2020-08-28 Ф. Хоффманн-Ля Рош Аг Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
MX2019011286A (es) 2017-03-26 2019-12-19 Takeda Pharmaceuticals Co Carboxamidas heteroaromaticas sustituidas de piperidinilo y piperazinilo como moduladores de gpr6.
WO2018177995A1 (de) * 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Trizyklische carboxamide zur bekämpfung von anthropoden
AU2018301381B2 (en) * 2017-07-11 2022-07-07 Cyteir Therapeutics, Inc. RAD51 inhibitors
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
EP3556760A1 (en) * 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
WO2019208812A1 (ja) * 2018-04-27 2019-10-31 国立大学法人大阪大学 ベンゾイソオキサゾール化合物
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
JP7310643B2 (ja) 2020-02-21 2023-07-19 三菱ケミカル株式会社 廃水処理用膜モジュール、廃水処理装置及び廃水処理方法
CR20230415A (es) 2020-11-30 2023-09-08 Kotobuki Pharmaceutical Co Ltd Compuesto de heteroarilcarboxamida
WO2023132208A1 (ja) * 2022-01-07 2023-07-13 国立大学法人大阪大学 心不全の予防および／または治療用医薬組成物
WO2023163203A1 (ja) * 2022-02-28 2023-08-31 国立大学法人大阪大学 腎臓疾患の予防および／または治療用医薬組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837282T2 (de) 1997-12-13 2007-11-08 Bristol-Myers Squibb Co. VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
MXPA01010292A (es) 1999-04-15 2002-10-23 Squibb Bristol Myers Co Inhibidores ciclicos de la proteina tirosina cinasa.
SI21099A (sl) 2000-07-26 2003-06-30 Bristol-Myers Squibb Company N-(5-(((5-alkil-2-oksazolil)metil)tio)-2-tiazolil) karboksamidni inhibitorji ciklin odvisnih kinaz
JP4052573B2 (ja) 2000-09-15 2008-02-27 バーテックス ファーマシューティカルズ インコーポレイテッド イソオキサゾールおよびｅｒｋのインヒビターとしてのその使用
US6818663B2 (en) 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
DE10250110A1 (de) * 2002-10-28 2004-05-13 Bayer Cropscience Ag Thiazol-(bi)cycloalkyl-carboxanilide
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP2008528585A (ja) 2005-01-26 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
KR20090004976A (ko) 2006-04-19 2009-01-12 아스테라스 세이야쿠 가부시키가이샤 아졸카르복사미드 유도체
AR063531A1 (es) * 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
CA2668210A1 (en) 2008-05-08
AU2007314342A1 (en) 2008-05-08
CA2668210C (en) 2013-03-12
JP5063700B2 (ja) 2012-10-31
AU2007314342B2 (en) 2013-02-21
EP2078003B1 (en) 2017-03-08
WO2008054702A1 (en) 2008-05-08
IL198397A0 (en) 2010-02-17
CN101578275A (zh) 2009-11-11
US20120328691A1 (en) 2012-12-27
US9206142B2 (en) 2015-12-08
KR20090075873A (ko) 2009-07-09
TW200829583A (en) 2008-07-16
JP2010508274A (ja) 2010-03-18
MX2009004786A (es) 2009-06-05
EP2078003A1 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
AR063721A1 (es) Derivados de anilinopiperazina y composicion farmaceutica
AR063531A1 (es) Derivados de anilinopiperazina y composicion farmaceutica
AR063545A1 (es) Derivados de tiazoles -1,3 aminosustituidos, composiciones farmaceuticas que las contienen y usos como agentes anticancer
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
AR069083A1 (es) Derivados heterociclicos de 1,3-tiazol inhibidores de proteinquinasas, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento o prevencion de trastornos proliferativos.
AR058554A1 (es) Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
BRPI0508966A (pt) composto, composição farmacêutica, e, uso de um composto
SI2651902T1 (en) Tricyclic pyrazolyl and pyrimidinylenones as antioxidant inflammatory modulators
AR030189A1 (es) Compuesto de benzotiazol, uso del mismo para preparar una composicion farmaceutica y dicha composicion farmaceutica
AR070127A1 (es) Pirrolo - pirimidinas y pirrolo -piridinas
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
ECSP099639A (es) Compuestos amino-5-[-4-(difluorometoxi)fenil sustituido]-5-fenilimidazolona como inhibidores de ?-secretasa
AR061629A1 (es) Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
MX2017010230A (es) Derivados de mono- y poliazanaftaleno sustituidos y su uso.
MY156747A (en) Isoxazolo-pyridine derivatives
PE20091236A1 (es) Derivados de pirimidina como immunomoduladores de tlr7
AR061858A1 (es) Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
AR064304A1 (es) Formulaciones de ansamicina y sus metodos de uso
AR084294A1 (es) Compuestos de 2-amino-4-ariltiazol, metodos para su sintesis y uso como antagonista de trpa1
AR066078A1 (es) Derivados de tetrahidroindol y tetrahidroindazol. procesos de obtencion, composiciones farmaceuticos y usos.
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AR056470A1 (es) Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa
JP2018505228A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal